logo-loader

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Published: 02:45 16 Sep 2021 EDT

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC). 

The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access basis for a group of 10 patients. 

This news follows a previous announcement (June 15) that CannEpil was added to Ireland’s Primary Care Reimbursement Service, meaning that all Irish patients have the full cost of CannEpil prescriptions covered by the health service.

Click here to read: MGC Pharmaceuticals - Rapid progress

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the...

on 11/13/2023